This article illustrates a subtype of alopecia areata characterized by acute diffuse hair loss and favorable outcome, as well as potential clues as to why someone may become grey in one night.

Alopecia areata equally affects men and women, usually at age 20-40 years. The lifetime risk of alopecia areata expression in the general population has been estimated to be 1.7%. [19] The disease ...

Alopecia areata affects millions of Americans regardless of age, race, or gender, manifesting as patchy hair loss across the scalp and sometimes other body areas. This autoimmune condition occurs ...

Matthew Riccardi was just 11 years old when he was diagnosed with the same condition: alopecia areata, an autoimmune disorder that targets hair follicles. Much like Campbell, the then-sixth grader ...

Reversible alopecia: Autoimmune types of alopecia, like alopecia areata, may be reversible. Treatments such as corticosteroids or immunotherapy help reduce immune attacks on hair follicles ...

If you’ve started to notice the early signs of hair loss, it’s easy to wonder what’s causing you to shed hair.

Patients share what they wish they had known before getting a diagnosis of alopecia areata, an autoimmune disease that causes ...

Diffuse alopecia areata, frontal fibrosing alopecia, central cicatricial centrifugal alopecia, traction alopecia and temporal triangular alopecia are all differential diagnoses for female pattern ...

Alopecia areata is an autoimmune disease that causes uncontrollable hair loss on the scalp, face, and body. The affected area can range from small patches on the scalp to total hair loss.

Nektar Therapeutics has concluded target enrolment in the Phase IIb REZOLVE-AA trial of its investigational biologic therapy, rezpegaldesleukin, for treating individuals with severe-to-very-severe ...

Alopecia totalis is a rare form of alopecia areata that causes widespread hair loss on your scalp, likely due to an autoimmune condition. How to Treat Telogen Effluvium Telogen effluvium is treatable.

Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in patients with severe-to-very-severe alopecia ...